Eutilex.Co.,Ltd (KOSDAQ:263050)
South Korea · Delayed Price · Currency is KRW 725.00
-15.00 (-2.03%)
At close: Jan 30, 2026
Eutilex.Co.,Ltd Company Description
Eutilex.Co.,Ltd. engages in the discovery and development of immunomodulatory antibody therapeutics to treat cancers and autoimmune diseases.
It develops EU101, a fully humanized anti-human 4-1BB monoclonal antibody; EU103, a fully humanized therapeutic monoclonal antibody; and EU501, an 4-1BB mAb-based, tumor antigen targeting bispecific antibodies.
The company was founded in 2008 and is headquartered in Seoul, South Korea.
Eutilex.Co.,Ltd
| Country | South Korea |
| Founded | 2008 |
| Industry | Biological Products, Except Diagnostic Substances |
| CEO | Byoung-Se Kwon |
Contact Details
Address: Suite 408, 4th Floor Seoul, 08591 South Korea | |
| Phone | 82 2 2071 3310 |
| Website | eutilex.com |
Stock Details
| Ticker Symbol | 263050 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Byoung-Se Kwon | Chief Executive Officer |